Discussing Eli Lilly's ASH25 data for Jaypirca's PFS benefit in treatment-naïve chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL)

Executed on:Jan 12, 2026 2:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Texas Oncology

Medical Oncologsist at Texas Oncology.
Manages 15 Myelofibrosis patients per year.
Fellowship trained at  in Hematology/Oncology at Louisiana State University Health Sciences; diplomat of the American Board of Internal Medicine.

Interview Goal

This conversation will focus on the treatment landscape and potential use of Jaypirca in CLL and SLL. 

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.